Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 15/20 | 0.50 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
| ▸ | SCN5A | Q14524 | 5/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | SCN2B | O60939 | 1/20 | 0.42 |
| ▸ | SCN1B | Q07699 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL680496 | 0.90 | MMP13 (0.51) | SCN9ABCL2L1MCL1MMP13HTT | |
| SCHEMBL680096 | 0.85 | SMN1; SMN2 (0.48) | SCN9ASCN5AMMP13HTTSMN1; SMN2 | |
| SCHEMBL16319859 | 0.84 | MMP1 (0.56) | SCN9ABCL2L1MCL1SCN5AHTT | |
| SCHEMBL680561 | 0.83 | MMP13 (0.65) | SCN9ABCL2L1MCL1MMP13HTT | |
| SCHEMBL678903 | 0.83 | BCL2L1 (0.52) | SCN9ABCL2L1MCL1SCN5AMMP13 | |
| SCHEMBL680466 | 0.81 | EZH2 (0.54) | SCN9ABCL2L1MCL1SCN5AMMP13 | |
| SCHEMBL680494 | 0.80 | SCN9A (0.57) | SCN9AMCL1SCN5AHTTSMN1; SMN2 | |
| SCHEMBL680487 | 0.80 | SCN9A (0.59) | SCN9ASCN5AHTTSMN1; SMN2HPGD | |
| SCHEMBL680556 | 0.80 | SCN9A (0.68) | SCN9ABCL2L1MCL1SCN5AHTT | |
| SCHEMBL680674 | 0.79 | SCN9A (0.57) | SCN9ABCL2L1MCL1SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593427-B1 | SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN | PFIZER LTD (GB) | 2014-12-24 | — | — | EP | disclosed |
| US-20120010207-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010207-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | SCN9A 13/4885BCL2L1 3284/4885MCL1 2739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.